跳至主要内容
临床试验/JPRN-UMIN000014298
JPRN-UMIN000014298已完成未知

Efficacy and safety of teneligliptin in patients with type 2 diabetes who responded insufficiently to dipeptidyl peptidase-4 (DPP-4) inhibitors - Efficacy and safety of teneligliptin in patients with type 2 diabetes who responded insufficiently to dipeptidyl peptidase-4 (DPP-4) inhibitors

aka Kinen Clinic0 个研究点目标入组 20 人开始时间: 2014年6月18日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Type-1 diabetes, diabetes due to a pancreatic disorder, or secondary diabetes due to conditions such as Cushing's syndrome and acromegaly (2) Application of contraindications contained in the package insert (3) Excessive alcohol consumption : mean daily intake of pure alcohol >=60g (4) Pregnant women, women suspected of being pregnant, or lactating women (5) Participation in the study is judged by the investigator or sub-investigator as inappropriate for any other reason

研究者

发起方
aka Kinen Clinic

相似试验